Table 1 |
||
|
Baseline Characteristics |
||
|
Engerix-B n = 19 |
Engerix B-CPG N = 19 |
|
|
|
||
|
Male (n) |
18 |
14 |
|
Prior Vaccine Failure (n) |
10 |
9 |
|
Age (Mean ± SD) |
42.9 ± 7.3 |
41.0 ± 7.4 |
|
CD4+ T cell count (Mean ± SD) |
543 ± 228 |
647 ± 262 |
|
Proportion with HIV RNA <50 copies/mL |
100% |
100% |
|
|
||
|
Angel et al. Journal of Immune Based Therapies and Vaccines 2008 6:4 doi:10.1186/1476-8518-6-4 |
||
